Notice: This company has been marked as potentially delisted and may not be actively trading. NewLink Genetics (NLNK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NLNK vs. EBS, RIGL, SGMO, XOMA, CDXS, VNDA, LXRX, VSTM, ACHV, and RGLSShould you be buying NewLink Genetics stock or one of its competitors? The main competitors of NewLink Genetics include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Sangamo Therapeutics (SGMO), XOMA (XOMA), Codexis (CDXS), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Achieve Life Sciences (ACHV), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. NewLink Genetics vs. Emergent BioSolutions Rigel Pharmaceuticals Sangamo Therapeutics XOMA Codexis Vanda Pharmaceuticals Lexicon Pharmaceuticals Verastem Achieve Life Sciences Regulus Therapeutics Emergent BioSolutions (NYSE:EBS) and NewLink Genetics (NASDAQ:NLNK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking. Which has more risk & volatility, EBS or NLNK? Emergent BioSolutions has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Does the media refer more to EBS or NLNK? In the previous week, Emergent BioSolutions had 2 more articles in the media than NewLink Genetics. MarketBeat recorded 2 mentions for Emergent BioSolutions and 0 mentions for NewLink Genetics. Emergent BioSolutions' average media sentiment score of 0.30 beat NewLink Genetics' score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the media. Company Overall Sentiment Emergent BioSolutions Neutral NewLink Genetics Neutral Which has higher earnings and valuation, EBS or NLNK? NewLink Genetics has lower revenue, but higher earnings than Emergent BioSolutions. NewLink Genetics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent BioSolutions$1.05B0.40-$760.50M-$4.10-1.88NewLink Genetics$940K171.95-$42.99M-$1.03-4.20 Do analysts prefer EBS or NLNK? Emergent BioSolutions currently has a consensus target price of $14.00, indicating a potential upside of 81.35%. Given Emergent BioSolutions' stronger consensus rating and higher probable upside, analysts clearly believe Emergent BioSolutions is more favorable than NewLink Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent BioSolutions 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33NewLink Genetics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EBS or NLNK more profitable? Emergent BioSolutions has a net margin of -18.55% compared to NewLink Genetics' net margin of -4,592.84%. Emergent BioSolutions' return on equity of -9.91% beat NewLink Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Emergent BioSolutions-18.55% -9.91% -3.31% NewLink Genetics -4,592.84%-41.50%-33.95% Does the MarketBeat Community favor EBS or NLNK? Emergent BioSolutions received 35 more outperform votes than NewLink Genetics when rated by MarketBeat users. However, 71.56% of users gave NewLink Genetics an outperform vote while only 66.88% of users gave Emergent BioSolutions an outperform vote. CompanyUnderperformOutperformEmergent BioSolutionsOutperform Votes42066.88% Underperform Votes20833.12% NewLink GeneticsOutperform Votes38571.56% Underperform Votes15328.44% Do insiders & institutionals believe in EBS or NLNK? 78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryEmergent BioSolutions beats NewLink Genetics on 13 of the 18 factors compared between the two stocks. Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades Get NewLink Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLNK vs. The Competition Export to ExcelMetricNewLink GeneticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.63M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-3.774.9166.6713.57Price / Sales171.95376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / Book2.059.686.475.93Net Income-$42.99M$154.43M$119.73M$225.73M NewLink Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLNKNewLink GeneticsN/A$4.33flatN/A+40.6%$161.63M$940,000.00-3.7755EBSEmergent BioSolutions4.4128 of 5 stars$9.27-7.0%N/A+264.2%$502.25M$1.05B-2.261,600Analyst UpgradeGap DownRIGLRigel Pharmaceuticals4.0008 of 5 stars$27.46+0.2%N/A+197.5%$483.71M$130.30M196.16147Analyst ForecastNews CoverageHigh Trading VolumeSGMOSangamo Therapeutics2.4765 of 5 stars$2.15-11.9%N/A+484.5%$447.68M$12.28M-2.87480Earnings ReportAnalyst ForecastAnalyst RevisionXOMAXOMA4.4451 of 5 stars$29.88+0.6%N/A+104.1%$351.99M$4.76M-8.5910Insider SellingShort Interest ↓CDXSCodexis4.2615 of 5 stars$3.74-7.4%N/A+88.3%$304.36M$70.14M-4.30250Analyst ForecastNews CoverageVNDAVanda Pharmaceuticals4.3127 of 5 stars$5.10-6.6%N/A+47.9%$297.38M$192.64M-18.21203Analyst ForecastPositive NewsLXRXLexicon Pharmaceuticals2.0112 of 5 stars$1.06-2.8%N/A-8.0%$261.01M$1.20M-1.41285Earnings ReportAnalyst ForecastAnalyst RevisionVSTMVerastem2.9685 of 5 stars$4.13+0.7%N/A-34.0%$183.83M$2.60M-1.2950ACHVAchieve Life Sciences1.5646 of 5 stars$4.39-3.1%N/A-17.3%$150.97MN/A-3.8820Analyst ForecastAnalyst RevisionNews CoverageGap UpRGLSRegulus Therapeutics2.7539 of 5 stars$1.50flatN/A+5.1%$98.25MN/A-1.4030Short Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies Emergent BioSolutions Competitors Rigel Pharmaceuticals Competitors Sangamo Therapeutics Competitors XOMA Competitors Codexis Competitors Vanda Pharmaceuticals Competitors Lexicon Pharmaceuticals Competitors Verastem Competitors Achieve Life Sciences Competitors Regulus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLNK) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share NewLink Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
